Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study

Fournier, Jean‐Pascal; Sommet, Agnès; Bourrel, Robert; Oustric, Stéphane; Pathak, Atul; Lapeyre‐Mestre, Maryse; Montastruc, Jean‐Louis

doi:10.1007/s00228-012-1283-9

Cited by 44 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, NSAIDs do not interact with CCBs and CAAs whose actions are apparently unrelated with renal/extrarenal production of prostaglandin31. The mechanism of action (MOA) has also been verified by a recent large-scale clinical study32.…”

Section: Resultsmentioning

confidence: 76%

Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects

Zhang¹,

Wang

Hu³

et al. 2015

Sci Rep

167

174

View full text Add to dashboard Cite

Drug-drug interaction (DDI) is an important topic for public health, and thus attracts attention from both academia and industry. Here we hypothesize that clinical side effects (SEs) provide a human phenotypic profile and can be translated into the development of computational models for predicting adverse DDIs. We propose an integrative label propagation framework to predict DDIs by integrating SEs extracted from package inserts of prescription drugs, SEs extracted from FDA Adverse Event Reporting System, and chemical structures from PubChem. Experimental results based on hold-out validation demonstrated the effectiveness of the proposed algorithm. In addition, the new algorithm also ranked drug information sources based on their contributions to the prediction, thus not only confirming that SEs are important features for DDI prediction but also paving the way for building more reliable DDI prediction models by prioritizing multiple data sources. By applying the proposed algorithm to 1,626 small-molecule drugs which have one or more SE profiles, we obtained 145,068 predicted DDIs. The predicted DDIs will help clinicians to avoid hazardous drug interactions in their prescriptions and will aid pharmaceutical companies to design large-scale clinical trial by assessing potentially hazardous drug combinations. All data sets and predicted DDIs are available at http://astro.temple.edu/~tua87106/ddi.html.

show abstract

Section: Resultsmentioning

confidence: 76%

Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects

Zhang¹,

Wang

Hu³

et al. 2015

Sci Rep

167

174

View full text Add to dashboard Cite

show abstract

“…A recent study analyzing 2680 hypertensive patients concomitantly treated with NSAIDs or acetaminophen demonstrated that NSAID use, particularly ibuprofen, was associated with a small increase in systolic blood pressure [62]. To evaluate the impact of NSAID therapy on hypertension and the need for hypertension treatment intensification, Fournier et al conducted a cohort study involving 5710 hypertensive subjects with a follow-up of about 4 years, demonstrating that exposure to NSAIDs, particularly diclofenac and piroxicam, led to intensification of treatment of hypertension, especially in patients treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers [63]. Furthermore, hypertensive patients are often treated with diuretics and angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and it has been previously demonstrated from a UK database of 487,372 patients treated with antihypertensive therapies that NSAIDs' addition to this double therapy significantly increased the risk of renal complications and acute kidney injury [64].…”

Section: Nsaids and Hypertensionmentioning

confidence: 98%

Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes

Gargiulo

Capodanno

Longo

et al. 2014

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

NSAIDs are used worldwide by more than 30 million people everyday, given their anti-inflammatory, analgesic and antipyretic effects. NSAIDs are approved for several common adult diseases, including acute and chronic musculoskeletal or inflammatory disease, osteoarthritis, rheumatoid arthritis and other arthritic conditions, as well as for children with juvenile idiopathic arthritis. Importantly, the population commonly taking NSAIDs is that of older individuals who also represent the population with the highest risk for cardiovascular (CV) and gastrointestinal adverse effects. In recent years, a growing body of evidence regarding potential risks from chronic use of NSAIDs has emerged. The aim of this review is to update the available data concerning chronic use of NSAIDs in patients with and without CV disease by analyzing the mechanisms of action, the interference of specific NSAIDs with the established CV protective role of low-dose aspirin, and the potential increased risk of myocardial infarction, stroke, hypertension, heart failure and atrial fibrillation.

show abstract

“…This is mediated through the inhibition of the production of vasodilatory prostanoids in the kidneys, thereby inducing vasoconstriction of afferent renal arterioles, fluid retention, and reduction in renal blood flow, promoting activation of the rennin–angiotensin system [2]. Although a well-designed trial, adjusting for drug exposure and comparing the hypertensive effects of NSAIDs, has not been conducted to date, a retrospective study reported that ibuprofen appears to be less likely than diclofenac and piroxicam to necessitate an intensification of antihypertensive treatment [86]. …”

Section: Pharmacodynamicsmentioning

confidence: 99%

PharmGKB summary

Mazaleuskaya

Theken

Gong³

et al. 2015

Pharmacogenetics and Genomics

128

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study

Abstract: Exposure to NSAIDs leads to an intensification of hypertension treatment, especially in patients treated with ACEIs or ARBs. Renin-angiotensin system blockers should be avoided whenever NSAIDs are prescribed.

Cited by 44 publications

References 30 publications

Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects

Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects

Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes

PharmGKB summary

Contact Info

Product

Resources

About